Clinical Trial

Extended Tricyle Project Indonesia for Extended-spectrum Beta-lactamase Positive Klebsiella Pneumoniae and Escherichia Coli

Study acronym: E-Trike
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 6, 2025 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
In 2019, Indonesia's first WHO Tricycle Project revealed alarming rates of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli across various sectors. The study found ESBL-producing E. coli in 40% of pregnant women, 57.7% of E. coli-induced bloodstream infections, 67.1% of broiler chicken, and 12.8% of total E. coli in water samples. In the first National Action Plan on Antimicrobial Resistance from Indonesia, the reduction of ESBL was identified as a clear goal. In E-Trike, Tricycle will be repeated, using the same methodology, to determine if a reduction has been achieved. Additionally, ESBL-positive Klebsiella pneumoniae will be included, as important pathogen for humans.
Trial Details
NCT Number NCT07106944
Lead Sponsor Erasmus Medical Center
Collaborators: Dr. Sulianti Saroso Hospital, Jakarta, Dr Cipto Mangunkusumo General Hospital, RSUP Persahabatan Hospital, Jakarta, Indonesia, National Institute for Public Health and the Environment (RIVM), Utrecht University
Conditions Carriage of ESBL-positive Escherichia Coli, Carriage of ESBL-positive Klebsiella Pneumoniae
Enrollment 100 participants
Start Date 2025-08-11
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-06